FindTrial
Sign In

Risk factors analysis and predictive model for tigecycline-induced acute pancreatitis

Risk factors analysis and predictive model for tigecycline-induced acute pancreatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072484
Enrollment
Unknown
Registered
2023-06-15
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trail group:none

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) All discharged patients who received tigecycline (Tig) from January 2015 to September 2022 2) Age =18 years 3) Patients who received the first dose of Tig 100mg and the maintenance dose of TIG 50mg for q12h

Exclusion criteria

Exclusion criteria: 1) Hospitalized for acute pancreatitis (AP) 2) AP appeared before Tig 3) Blood amylase/lipase levels increased =3 times before Tig use 4) Patients with pancreatic cancer

Design outcomes

Primary

MeasureTime frame
acute pancreatitis;—

Secondary

MeasureTime frame
Acute liver injury(ALI) ;—

Countries

China

Contacts

Public ContactYun Lu

Zhongnan Hospital of Wuhan University

luyun@znhospital.cn+86 139 8626 7619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026